FirstIgnite is supporting Oklahoma State University’s novel therapeutic targets for diabetes technology, which has shown potential in enhancing glucose transport within striated muscle and adipose tissue of diabetic mice. The Oklahoma State team is specifically seeking organizations who would be interested in giving feedback on their research and potentially pursuing it further.
This technology is applicable to development of novel pharmacological targets in diabetic patients, therapeutic interventions to regulate whole-body glucose homeostasis, and cardiokine-based treatments for diabetes and metabolic disorders. The global diabetes treatment market is worth $92.97 billion in 2023 and is expected to increase to $118.77 billion by 2028.
Oklahoma State University’s novel therapeutic targets for diabetes technology is ready for collaboration. Is your company the right fit? If you’d be available for a conversation with the Oklahoma State University team, you can schedule a time directly on their team’s calendar here.
